
AlphaNooner by AdvisorShares
AdvisorShares
ALPHANOONER Markets. Themes. The people investing in what comes next.
AlphaNooner - A Veteran’s Journey Through Trauma & Psychedelic Medicine with Graham Ginn
Episode discussion: Veteran Graham Ginn discusses psychedelic medicine, trauma healing, and legislative advocacy for psilocybin research.
Speakers’ claims: Graham Ginn, a Navy veteran, shares his transition from skepticism to advocacy for psychedelic medicine after a transformative experience during a mental health crisis. He recounts using plant entheogens to cope with a stage four throat cancer diagnosis, claiming the substances aided in pain management and psychological resilience. Ginn highlights legislative efforts such as Texas HB 1802 and the federal Freedom to Heal Act as key vehicles for descheduling and research. The discussion emphasizes the importance of professional integration, medical screening for drug interactions, and the distinction between regulated therapy and unlicensed facilitation.
AlphaNooner - Cannabis After the 2026 Midterms: What Changes? with Todd Harrison
Episode discussion: Todd Harrison argues 2026 midterms and DEA rescheduling will drive cannabis sector consolidation and profitability.
Speakers’ claims: Todd Harrison argues that the 2026 midterm elections defeated prohibitionist efforts in states like Massachusetts and Idaho, while opening new markets in Pennsylvania and Wisconsin. He anticipates a positive DEA decision to reschedule cannabis from Schedule I to Schedule III, which would restore IRS Section 280E tax deductions and significantly improve company profitability. Harrison identifies the December 11th intoxicating hemp ban as a catalyst that will drive consumers back to regulated dispensaries. He expects 2027 to be a 'show me year' for double-digit growth as the market consolidates around fewer, larger players. Harrison highlights Village Farms and TerrAscend as undervalued opportunities relative to peers like Aurora.
AlphaNooner - Cannabis Rescheduling & the Psychedelic Selloff: What Matters Now with Dan Ahrens
Episode discussion: Dan Ahrens argues cannabis rescheduling is an administrative process unaffected by election outcomes, while psychedelic stocks overreacted to Otsuka's NDA filing.
Speakers’ claims: Dan Ahrens discusses the recent Schwab Impact Conference, noting that cannabis rescheduling is an administrative process handled by the DOJ and Administrative Law Judges, making it immune to legislative stalemate in Congress. He highlights that the upcoming hemp ban is driving revenue growth for licensed dispensaries by capturing displaced market share. Regarding psychedelics, Ahrens argues the recent selloff following Otsuka’s New Drug Application (NDA) filing was an overreaction, as the nonprofit entity lacks commercial infrastructure and must navigate existing patents held by competitors like Compass Pathways. He also clarifies that cannabis ETFs using total return swaps can exceed 100% exposure without incurring margin debt or interest payments.